Medical News

RSS
O2h signs agreement to provide discovery services to Karyopharm Therapeutics

O2h signs agreement to provide discovery services to Karyopharm Therapeutics

Merck Serono reports long-term follow-up data of cilengitide Phase II study for recurrent glioblastoma

Merck Serono reports long-term follow-up data of cilengitide Phase II study for recurrent glioblastoma

KMI receives $2.8M grant to support delivery of teletherapy service to stroke survivors in rural areas

KMI receives $2.8M grant to support delivery of teletherapy service to stroke survivors in rural areas

Managing Myeloma launches MTR tool to help practitioners treat patients with multiple myeloma

Managing Myeloma launches MTR tool to help practitioners treat patients with multiple myeloma

Simcere Pharmaceutical to increase stake in Jilin Boda

Simcere Pharmaceutical to increase stake in Jilin Boda

Data shows VB-201 controls inflammatory responses associated with autoimmune diseases, atherosclerosis

Data shows VB-201 controls inflammatory responses associated with autoimmune diseases, atherosclerosis

Adeona completes 50% enrollment in Part 2 CopperProof-2 study of oral zinc cysteine for Alzheimer's Disease

Adeona completes 50% enrollment in Part 2 CopperProof-2 study of oral zinc cysteine for Alzheimer's Disease

Immersion signs non-exclusive, worldwide license agreement with Simbionix USA

Immersion signs non-exclusive, worldwide license agreement with Simbionix USA

GSK submits BENLYSTA MAA for systemic lupus erythematosus

GSK submits BENLYSTA MAA for systemic lupus erythematosus

Pharmacoeconomic methods influence only 13% of hospital formulary system decisions: Survey

Pharmacoeconomic methods influence only 13% of hospital formulary system decisions: Survey

Cytheris completes €12 million Series D financing

Cytheris completes €12 million Series D financing

Millennium reports on data of VELCADE for multiple myeloma from 2010 ASCO oral presentations

Millennium reports on data of VELCADE for multiple myeloma from 2010 ASCO oral presentations

ASHP honors First DataBank pharmacist with the title of Fellow for excellence in pharmacy practice

ASHP honors First DataBank pharmacist with the title of Fellow for excellence in pharmacy practice

Sanofi-aventis reports new 1-year data from teriflunomide Phase II study for relapsing multiple sclerosis

Sanofi-aventis reports new 1-year data from teriflunomide Phase II study for relapsing multiple sclerosis

AMG 386 demonstrates antitumor activity in Phase 2 trial involving patients with recurrent ovarian cancer

AMG 386 demonstrates antitumor activity in Phase 2 trial involving patients with recurrent ovarian cancer

Genta reports combined data from Genasense Phase 3 trials for advanced melanoma

Genta reports combined data from Genasense Phase 3 trials for advanced melanoma

Strained relationship with parents following stroke increases depression in daughters: Study

Strained relationship with parents following stroke increases depression in daughters: Study

TransMedia to publicize Protectus Automatic, Self-Sheathing Safety Syringe

TransMedia to publicize Protectus Automatic, Self-Sheathing Safety Syringe

PharmaTelevision offers biopharma companies opportunity to reach key decision makers in financial sector

PharmaTelevision offers biopharma companies opportunity to reach key decision makers in financial sector

Bevacizumab extends progression-free survival in women with advanced ovarian cancer

Bevacizumab extends progression-free survival in women with advanced ovarian cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.